Viewing Study NCT06464965



Ignite Creation Date: 2024-07-17 @ 11:34 AM
Last Modification Date: 2024-10-26 @ 3:32 PM
Study NCT ID: NCT06464965
Status: RECRUITING
Last Update Posted: 2024-06-18
First Post: 2024-06-13

Brief Title: Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer
Sponsor: Zhejiang Provincial Peoples Hospital
Organization: Zhejiang Provincial Peoples Hospital

Study Overview

Official Title: A Phase I Clinical Study of Cord Blood-Derived CAR-NK Cells Targeting Claudin182 in the Treatment of Advanced Gastric Cancer and Advanced Pancreatic Cancer
Status: RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Main Objective To study the maximum tolerated dose MTD and dose-dependent toxicity DLT of cord blood-derived CAR-NK cells CB CAR-NK182 targeting Claudin182 in patients with advanced gastric cancer and advanced pancreatic cancer

Secondary Objective To evaluate the efficacy of CB CAR-NK182 in patients with advanced gastric cancer and advanced pancreatic cancer overall objective tumor response rate ORR disease control rate DCR progression-free survival PFS overall survival OS duration of response DOR etc

To evaluate the CAR-NK amplification and persistence of CB CAR-NK182 in the blood of patients with advanced gastric cancer and advanced pancreatic cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None